Sponsor of the Day:
Jerkmate
https://www.lvivpost.net/peole/bogdanu-ilkivu-zibraly-neobhidnu-sumu-na-preparat-elevidys/
Богдану Ільківу зібрали необхідну суму на препарат Elevidys – Львівська Пошта
Apr 20, 2026 - Закінчився збір коштів для Богдана Ільківа з Бродів, який хворіє на м'язову дистрофію Дюшена. На лікування зібрали 2,9 млн доларів.
elevidys
https://www.biospace.com/business/after-sareptas-annus-horribilis-elevidys-sales-expected-to-continue-downward-spiral
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral - BioSpace
Feb 27, 2026 - After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy...
annus horribilissales expecteddownward spiralelevidyscontinue
https://www.statnews.com/2026/04/16/roche-elevidys-pivotal-trial-europe-sarepta/
Roche to launch another Elevidys trial, hoping to win E.U. approval
Apr 16, 2026 - European regulators last year said the Duchenne gene therapy, which is sold by Sarepta in the U.S., failed to show clear benefits.
win erochelaunchanotherelevidys
https://www.biopharmadive.com/news/fda-elevidys-nuvalent-alk-zymeworks-her2-nxera-layoffs/805607/
FDA limits Elevidys use; Nxera to lay off staff | BioPharma Dive
Nov 17, 2025 - Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for...
biopharma divefdalimitselevidysuse